Core Viewpoint - The company, CanSino Biologics, has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its vaccine development efforts [1] Group 1: Vaccine Development - The inhaled tuberculosis vaccine (5-type adenovirus vector) has officially started Phase I clinical trials in Indonesia, with the first subject enrolled [1] - Currently, the only vaccine available for tuberculosis prevention globally is the BCG vaccine, which has limitations in long-term efficacy and cannot be enhanced through booster shots [1] - The company has developed a first-generation innovative tuberculosis booster vaccine aimed at BCG-vaccinated populations, which has completed Phase Ia and Ib clinical trials in Canada, demonstrating safety and efficacy as a booster [1] Group 2: Technology and Delivery Method - The company has leveraged technology from its inhaled COVID-19 vaccine development to establish a comprehensive inhalation pharmaceutical and quality control system, enhancing the first-generation product and adding antigen components [1] - The inhaled tuberculosis booster vaccine is designed to be delivered via nebulization, which is expected to stimulate pulmonary immune responses to eliminate tuberculosis bacteria and control latent infections [1] Group 3: Clinical Trial Objectives - The Phase I clinical trial aims to investigate the safety and immunogenicity of a single dose of the inhaled tuberculosis booster vaccine in adults aged 18 to 49 [1]

Core Viewpoint - The company has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its development of a novel vaccine to enhance protection against tuberculosis [1] Group 1: Vaccine Development - The inhaled tuberculosis vaccine, developed using a 5-type adenoviral vector, has officially started its Phase I clinical trials in Indonesia, with the first subject enrolled [1] - The existing BCG vaccine is the only globally available vaccine for tuberculosis prevention, but its efficacy diminishes over time and cannot be enhanced through booster shots [1] - The company has developed a first-generation innovative tuberculosis booster vaccine aimed at individuals who have received the BCG vaccine, which has shown safety and efficacy in previous clinical trials conducted in Canada [1] Group 2: Technological Advancements - The company has leveraged its technology from the development of inhaled COVID-19 vaccines to establish a comprehensive inhalation pharmaceutical and quality control system [1] - The upgraded inhaled tuberculosis booster vaccine includes additional antigen components and is designed to be delivered via nebulization, potentially stimulating pulmonary immune responses to eliminate tuberculosis bacteria and control latent infections [1]

Core Viewpoint - The company has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its vaccine development efforts [1] Group 1: Vaccine Development - The inhaled tuberculosis vaccine, developed using a 5-type adenovirus vector, aims to enhance immunity in individuals previously vaccinated with the BCG vaccine [1] - The BCG vaccine is currently the only vaccine available for tuberculosis prevention, but its efficacy diminishes over time, necessitating the development of a booster vaccine [1] - The company has successfully completed Phase Ia and Ib clinical trials in Canada, demonstrating the safety and efficacy of the tuberculosis booster vaccine [1] Group 2: Technological Advancements - The company has leveraged its experience from developing inhaled COVID-19 vaccines to establish a comprehensive inhalation pharmaceutical and quality control system [1] - The upgraded inhaled tuberculosis booster vaccine includes additional antigen components and is designed to be delivered via nebulization, potentially stimulating pulmonary immune responses [1] - This innovative delivery method aims to clear tuberculosis bacteria, control latent infections, and provide preventive effects against the disease [1]

CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 基 於 吸 入 用 新 冠 疫 苗 開 發 的 技 術 累 積，本 公 司 建 立 了 完 整 的 吸 入 藥 學、質 量 控 制體系，升級第一代產品，同時增加了抗原組分，開發了吸入用結核病加強疫苗， 通過霧化吸入的方式遞送，有望可以激發肺部免疫應答，從而清除結核菌，控制 潛伏感染，並可實現預防感染的效果。 – 1 – I期臨床試驗於印度尼西亞開展，目的是在18至49歲的成年人中探究接種一劑吸 入用結核病加強疫苗的安全性和免疫原性。 本公司股東及潛在投資者在買賣本公司股份時務請審慎行事。 承董事會命 康希諾生物股份公司 自願公告 吸入用結核病加強疫苗於印度尼西亞 啟 動I期臨床試驗並完成首例受試者入組 本 公 告 由 康 希 諾 生 物 股 份 公 司（「本公司」）自 願 ...

康希诺生物股份公司（以下简称"公司"）开发的吸入用肺结核疫苗（5型 腺病毒载体）（以下简称"吸入用结核病加强疫苗"）近日于印度尼西亚启动I 期临床试验，并完成I期临床首例受试者入组。 一、产品基本情况 证券代码：688185 证券简称：康希诺 公告编号：2025-041 康希诺生物股份公司 自愿披露关于吸入用肺结核疫苗（5型腺病毒载体）于 印度尼西亚启动I期临床试验并完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 11 月 14 日 目前，卡介苗是全球唯一可用于预防结核病的疫苗，在全球范围内被广泛接 种，其对预防婴幼儿结核病发挥重要作用，但卡介苗保护力会随时间减弱，无法 通过加强免疫接种增强疫苗的保护效果。针对此不足，公司研发了第一代全球创 新的结核病加强疫苗用于卡介苗接种人群，该款疫苗于加拿大完成了 Ia 及 Ib 期 临床试验，临床数据证明了该候选疫苗的安全性和作为卡介苗加强疫苗的有效 性，以及黏膜免疫的优越性。 基于吸入用新冠疫苗开发的技术累积，公司建立了完整的吸入药学、质量控 ...

康希诺11月13日公告，公司开发的吸入用肺结核疫苗（5型腺病毒载体）近日于印度尼西亚启动I期临床 试验，并完成首例受试者入组。该疫苗为第一代全球创新的结核病加强疫苗，通过雾化吸入的方式递 送，有望激发肺部免疫应答，控制潜伏感染，并可实现预防感染的效果。 ...

Core Viewpoint - The company, CanSino (688185.SH), has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its development process [1] Group 1: Clinical Trial Details - The Phase I clinical trial aims to explore the safety and immunogenicity of a single dose of the inhaled tuberculosis vaccine (Ad5 vector) in adults aged 18-49 [1] - The first subject has been enrolled in the Phase I clinical trial, indicating progress in the vaccine's development timeline [1]

Core Viewpoint - The company, CanSino (688185.SH), has initiated Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia, marking a significant step in its vaccine development efforts [1] Group 1: Clinical Trial Details - The Phase I clinical trial aims to explore the safety and immunogenicity of a single dose of the inhaled tuberculosis vaccine (Ad5 vector) in adults aged 18-49 [1]

Core Viewpoint - The "China's Top 100 Future Unicorns" list aims to identify and accelerate the growth of potential unicorn companies in China over the next decade, serving as a significant indicator of innovation in the economy [3][5]. Group 1: Historical Performance - Over 16 years, the list has recognized 1,302 companies, with 130 achieving IPOs, 106 being acquired by larger firms, and 188 becoming industry-leading unicorns [4][6]. - The annual "Future Unicorn Conference" has become a key event for emerging unicorns, providing networking and investment opportunities [4]. Group 2: Notable Companies - The list includes several well-known companies that have reached significant market valuations, such as Xiaomi, Meituan, and NIO, which were among the first to be recognized [7][8]. - A selection of companies that have recently become unicorns includes New Stone Unmanned Vehicles, which raised over $600 million in its D round, and Galaxy General, which secured 1.1 billion RMB in its A+ round [10][11]. Group 3: Future Prospects - The ongoing search for high-growth companies valued between $100 million and $1 billion is emphasized, with a call for nominations for the 2025 list [13]. - The initiative aims to celebrate not just valuation but also the intrinsic value of these emerging leaders in the business landscape [13].

CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 2025年11月27日（星 期 四）舉 行 之 2025年第二次臨時股東大會適用的代表委任表格 本人╱吾等 (附 註1) （姓名） 1. 請 用 正 楷 填上全名及地址。 2. 請填上登記於 閣下名下的本公司股份數目。如未有填上股份數目，則本代表委任表格將被視為與本公司所有以 閣下名義登記的股份有關。 地址為 （地址） 為 康 希 諾 生 物 股 份 公 司（「本公司」） 股 H股 (附 註2) 的登記持有人，茲委任 （附註3） 大會主席或 （姓名） 地址為 （地址） 為本人╱吾等的代表，代表本人╱吾等出席本公司謹訂於2025年11月27日（星 期 四）下 午 二 時 正 假 座 中 華 人 民 共 和 國 天 津 市 河 東 區 衛 國 道126 號天津東凱悅酒店二層悅賓廳1舉行的2025年 第 二 次 臨 時 股 東 大 會（及 其 任 何 續 會），以 審 議 並 酌 情 通 過 召 開 上 述 大 會 的 通 告 所 載 的 決 議 並 於 該 大 會（及 其 任 何 ...